Peter de Haan

Founder at Amarna Therapeutics BV

Distribution Services

Health Services

Profile

Peter de Haan is the founder and Chief Scientific Officer of Amarna Therapeutics BV, which is founded in 2008.
He is currently a Non-Executive Director at Barranco Resources NL.

Peter de Haan active positions

Companies	Position	Start
Barranco Resources NL Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia.	Director/Board Member	-
Amarna Therapeutics BV Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.	Founder	31/12/2007

All active positions of Peter de Haan

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Peter de Haan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Barranco Resources NL Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia.	Distribution Services
Amarna Therapeutics BV Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands.	Health Services